Notifying patients and providers about the rosiglitazone cardiovascular safety alert led to sweeping changes in drug therapy that were initiated by both physicians and patients.
Amy Wei, PharmD
Advertisement
Articles by Amy Wei, PharmD
Advertisement
Latest Updated Articles
- Clinical Consequences of Disseminating the Rosiglitazone FDA Safety Warning
Published: May 1st 2010 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Cytokines Linked With Drug Resistance in Ovarian Cancer, but Underlying Mechanisms Remain Unclear
2
CHEST 2025 Highlights: Future of Respiratory Vaccines and the Impact of Federal Funding Cuts
3
Elinzanetant Shows Consistent Efficacy, Safety, and Sleep Benefits Across Studies
4
Mepolizumab Reduces Health Care Resource Utilization, Work Impairment in Severe Asthma
5
